One of the leaders in volume daily for penny stocks, Advanced Cell Technology, Inc. (OTC: ACTC), a regenerative medicine working with stem cells, looks forward to conducting Phase I/II clinical trial for Stargardt’s Macular Dystrophy (SMD) after the Wills Eye Institute in Philadelphia received institutional review board (IRB) approval. SMD is a ...
15
FEB
FEB
0
Share
